Inotiv Acquires Genetic Toxicology Assets from MilliporeSigma’s BioReliance® Portfolio

Inotiv, a research organization specializing in nonclinical and analytical drug discovery and development services, acquired genetic toxicology assets from MilliporeSigma’s BioReliance® portfolio, including standard operating procedures, stock cultures, historic control data and client list. While Inotiv did not disclose the specific financial terms, the transaction consists of a sales-based royalty agreement and does not require upfront funding from the Company.

Robert Leasure, Jr., President and CEO of Inotiv, commented, “This transaction with MilliporeSigma adds genetic toxicology to our suite of internal capabilities. We now have assembled in-house all of the critical nonclinical services necessary to support our clients’ goals of advancing to human clinical trials.”

MilliporeSigma is discontinuing their Genetic Toxicology operations. The agreement with Inotiv is designed to ensure continuity of services for existing clients. Inotiv also plans to offer employment to certain MilliporeSigma employees who otherwise may have been displaced.

“Evaluation of the potential for novel therapeutics to interact with and alter DNA is a key element of the safety assessment of those drug candidates,” said John E. Sagartz, Chief Strategy Officer of Inotiv. “Inotiv historically has relied on other vendors to provide these key assessments. I’m excited to announce the addition of the BioReliance® assets and Dr. Krishna, and we look forward to developing the genetic toxicology business. We believe this is another significant milestone for Inotiv and our clients.”

Dr. Krishna commented, “I am delighted to join Inotiv with the task of expanding the service offering to include genotoxicity capabilities and look forward to leveraging the assets of the BioReliance® portfolio to assist our clients in the development of safe novel therapeutics.”